Section Arrow
ZBIO.NASDAQ
- Zenas Biopharma Inc.
Quotes are at least 15-min delayed:2026/08/01 19:20 EDT
Regular Hours
Last
 31.44
-0.83 (-2.57%)
Day High 
32.95 
Prev. Close
32.27 
1-M High
34.05 
Volume 
452.23K 
Bid
29
Ask
32
Day Low
30.6 
Open
32.69 
1-M Low
25.48 
Market Cap 
2.04B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 31.39 
20-SMA 29.83 
50-SMA 23.88 
52-W High 44.6 
52-W Low 13.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-9.10/-4.34
Enterprise Value
2.04B
Balance Sheet
Book Value Per Share
5.32
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.00M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.